Healthcare Roundup –Kamada distribute biosimilars, Mylan launches Herceptin biosimilar, Aleafia up 4%

医疗保健综述——Kamada分销生物仿制药,迈兰推出赫赛汀生物仿制药,Aleafia股价上涨 4%
Published on: December 2, 2019
Author: Amy Liu

Kamada to distribute six biosimilars in Israel

Kamada Ltd. (KMDA +0.5%) inks an agreement with Alvotech to commercialize the latter’s portfolio of six biosimilars in Israel, once approved. The first product, PF708 (branded as Bonsity), a biosimilar to Eli Lilly’s osteoporosis med Forteo (teriparatide), should be launched in 2022.

Financial terms are not disclosed.

ASLAN Pharma launches equity offering

On cue from its ASLAN004-stoked run-up, ASLAN Pharmaceuticals (ASLN +49.2%) commences a public offering of American Depositary Shares (ADSs). Price, volume and terms have yet to be announced.

FTC signs off on Amgen/BeiGene deal

The U.S. Federal Trade Commission (FTC) grants antitrust clearance for Amgen’s (AMGN -0.5%) previously announced collaboration with BeiGene (BGNE -0.6%) that includes a $2.7B investment (20.5% stake) in the Chinese biotech.

Aleafia up 4% on $7M cannabis sale

Aleafia Health (OTCQX:ALEAF) is up 4% in early trade in response to an order from a licensed producer in Canada for 2,840 kg of dried cannabis flower at $2.50 per gram for a total of $7.1M. The transaction, consisting of three shipments, will be completed before the end of next month.

Mylan launches Herceptin biosimilar in U.S.

Mylan N.V. (NASDAQ:MYL) and development partner Biocon Ltd. (OTC:BCNQY) announce the U.S. commercial launch of Ogivri (trastuzumab-dkst), a biosimilar to Roche’s (OTCQX:RHHBY) Herceptin.

Mylan owns exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand, the EU and European Free Trade Association countries. Biocon has co-exclusive rights with Mylan in the rest of the world.

Biotechnology Healthcare Services Life Science Pharmaceutical